Navigation Links
SGX Pharmaceuticals Announces Financial Results for the Three and Nine Months Ended September 30, 2007
Date:11/13/2007

increased costs related to the development of our MET inhibitors. The decrease of $4.6 million for the nine month period was primarily attributable to a decrease of costs incurred for Troxatyl(TM) clinical trial activities, a reduction in subcontractor expenditures associated with our federal research grant, and lower depreciation expense.

General and administrative expenses for the three months ended September 30, 2007 and 2006 were $2.1 million and $1.9 million, respectively. General and administrative expenses for the nine months ended September 30, 2007 and 2006 were $6.4 million and $7.4 million, respectively. The increase of $0.2 million for the three month period was primarily attributable to increased professional services. The decrease of $1.0 million for the nine month period was primarily attributable to a decrease in non-cash stock-based compensation expense, together with a decrease in recruiting, salaries and professional services.

SGX reported a net loss attributable to common stockholders for the three months ended September 30, 2007 of $4.8 million, or $0.31 per share. This compares with a net loss attributable to common stockholders for the three months ended September 30, 2006 of $3.4 million, or $0.23 per share. For the nine months ended September 30, 2007, the net loss attributable to common stockholders was $9.9 million, or $0.65 per share. This compares with a net loss attributable to common stockholders for the nine months ended September 30, 2006 of $23.2 million, or $1.74 per share.

About SGX Pharmaceuticals

SGX Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics. The SGX oncology pipeline includes drug candidates from its FAST (TM) drug discovery platform, such as next generation BCR-ABL inhibitors being developed by SGX and in partnership with Novartis and MET tyrosine kinase inhibitors, including SGX523, and potent JAK2 inhibitors
'/>"/>

SOURCE SGX Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Las Vegas, NV (PRWEB) September 17, 2014 ... Lewis that shows dog owners the true poisonous ingredients in ... homemade dog food recipes has caught the attention of Shane ... their dogs are just as much of a family member ... tragic when their dog dies earlier than it should due ...
(Date:9/16/2014)... the UK report a poorer experience of care during ... on their care, suggests a new study published today ... Obstetrics and Gynaecology ( BJOG ). , Differences ... demonstrated in many areas and have provided the focus ... observed inequalities. , The Oxford University study, funded by ...
(Date:9/16/2014)... Keep that sexy decolletage as you age, and frame ... Face Whisperer Neck & Decollete Cream is made ... Sublime Beauty®. "It contains rich ingredients to care for the ... A special ingredient is Argireline, known as the natural botox, ... comes in an airless pump bottle, and is part of ...
(Date:9/16/2014)... UT (PRWEB) September 16, 2014 ... Solution, published new information on transitioning employees to ... Benefits, with the Affordable Care Act (ACA) in ... will be steering some or all of their ... no surprise. With guaranteed issue plans, coverage for ...
(Date:9/16/2014)... 17, 2014 UWDress.com, the well-known wedding ... elegant evening wear assortment online. Additionally, the firm ... people can access big discounts now, up to 62 ... evening gowns are charming; it has won a lot ... evening outfits, it is also providing big savings on ...
Breaking Medicine News(10 mins):Health News:Dog Food Secrets: Review Exposes Andrew Lewis’ Guide to Happier, Healthier Dogs with Homemade Dog Food 2Health News:A greater focus on socially disadvantaged women is needed to improve maternity care in England 2Health News:15% Off Face Whisperer® Neck & Decollete Cream Now from Sublime Beauty; Care For This Delicate Skin That Shows Age Quickly 2Health News:Zane Benefits Publishes New Information on Transitioning Employees to Individual Health Insurance 2Health News:New Elegant Evening Wear Assortment Released By UWDress.com 2
... as likely to miscarry during the first three weeks of ... study is the first of it’s kind to have established ... at an early stage. ,Cortisol is a hormone ... this hormone serve as a reliable stress indicator. Nearly 61 ...
... officially confirmed the cause of three dead swans found in Bulgaria ... It has said that it has confirmed it from the country's ... Lake in the Varna region and at Burgas beach have tested ... necessary steps by completely cordoning it off from the public. An ...
... is the second-biggest killer of women in UK. The recent reports ... they take a genetic breast cancer test caused a lot of ... 40,000 diagnoses are done each year and 13,000 deaths are expected. ... would not ask for women to take genetic breast cancer tests. ...
... spurt of fungal infections in contact lens wearers and this ... seven reported last month. //This takes the overall cases since ... infections and the Singapore National Eye Centre (SNEC) has treated ... and Lomb's (B&L) ReNu with MoistureLoc solution and the Health ...
... euthanasia campaigner Dr Philip Nitschke does not possess a license ... informs participants of their legal rights about ending their lives., ... registered as a doctor to carry out his euthanasia workshops. ... he needs a licence. He faces a criminal conviction if ...
... to a study by Emory University researcher Chensheng "Alex" ... two common pesticides used in U.S. agricultural production.'// ... of children with organic food items. The result was ... ,As stated by Dr. Lu, "The ...
Cached Medicine News:Health News:Early Miscarriage Common In Women Under Stress 2Health News:Health insurance in the future would depend on genetic test results 2
(Date:9/16/2014)... , Sept. 16, 2014 Adaptive Biotechnologies, ... Sequencing (NGS) to profile the adaptive immune system, is ... as Chief Commercial Officer (CCO). The addition of ... recent key hires from leading global healthcare companies, including ... (General Counsel) from Genomic Health and Sean ...
(Date:9/16/2014)... Sept. 16, 2014 EHE International, the recognized leader ... physician network, today announced that David Abrams M.D . ... an EHE-certified preventive care center. Through David Abrams M.D ... region now have greater access to EHE,s preventive care programs ... is proud to add Dr. Abrams M.D. to its growing ...
(Date:9/16/2014)... , Sept. 16, 2014 QPID Health , ... to new headquarters in Boston and ... headquarters will be at 175 Franklin Street in ... marketing teams. QPID Health,s new Southern California ... Carlsbad.  The expansion will help meet the demands of customers ...
Breaking Medicine Technology:Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 3EHE International Certifies David Abrams M.D. as Its Newest Partner 2QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2
... 3, 2010 Cardiogenesis Corporation (OTCQB: CGCP), a leading ... diffuse coronary artery disease, today reported financial results for ... 30, 2010. Revenue for the third quarter ... year third quarter revenue of $2,134,000.  Gross margin was ...
... NxStage Medical, Inc. (Nasdaq: NXTM ), ... that it has expanded its Medisystems® in-center product portfolio ... to the terms of the strategic Agreement with Vasc-Alert ... in the United States.   Vasc-Alert, a ...
Cached Medicine Technology:Cardiogenesis Reports Third Quarter 2010 Results 2Cardiogenesis Reports Third Quarter 2010 Results 3Cardiogenesis Reports Third Quarter 2010 Results 4Cardiogenesis Reports Third Quarter 2010 Results 5Cardiogenesis Reports Third Quarter 2010 Results 6NxStage® Expands Product Portfolio With Innovative Patient Access Surveillance Solution From Vasc-Alert™ 2NxStage® Expands Product Portfolio With Innovative Patient Access Surveillance Solution From Vasc-Alert™ 3
... original ultrasonic cement and ... an 11-year clinical history. ... array of tool tips ... applications, cemented and porous ...
... media meets today's ASHRAE challenges ... reduction. The unique, patented non-woven ... filters creates a media which ... to initial efficiency, average efficiency, ...
BRAT 2 Autologous Blood Recovery System gives performance, speed, versatility, and quality processing. , ,The BRAT 2 is now available with on-board Vacuum, programmability, plasma sequestration, Data...
The hipGRIP® is a twenty piece modular lateral positioning system which provides positive pelvis control with an innovative positioning system....
Medicine Products: